Short-term prognostic factors for primary sclerosing cholangitis

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 22, Issue 6, 2015, Pages 486-490

  Watanabe, Takeo ^a,b   Hirano, Kenji ^b,c   Tada, Minoru ^b   Isayama, Hiroyuki ^b   Mizuno, Suguru ^b,d   Arizumi, Toshihiko ^e   Toda, Nobuo ^e   Sugawara, Yasuhiko ^f   Kokudo, Norihiro ^f   Koike, Kazuhiko ^b  

^a Mutual Aid Association of Public School Teachers   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JCHO Tokyo Takanawa Hospital   (Japan)

^d Shinagawa ku   (Japan)

^e MITSUI MEMORIAL HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Alkaline phosphatase; MELD score; Primary sclerosing cholangitis; Prognosis; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BLEEDING; CADAVER DONOR; CLINICAL FEATURE; CLINICAL LABORATORY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAPANESE (PEOPLE); LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; NORMAL VALUE; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SHORT TERM SURVIVAL; THROMBOCYTE COUNT; VARICEAL BLEEDING; ADOLESCENT; BLOOD; CHILD; COMPLICATION; DISEASE COURSE; END STAGE LIVER DISEASE; ENZYMOLOGY; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; SCLEROSING CHOLANGITIS; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALKALINE PHOSPHATASE; BIOMARKERS; CHILD; CHOLANGITIS, SCLEROSING; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS; YOUNG ADULT;

EID: 84929921399     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.238     Document Type: Article

References (22)

1. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, et al., Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 1980; 21: 870-7.
2. Maggs JRL, Chapman RW,. An update on primary sclerosing cholangitis. Curr Opin Gastroenterol. 2008; 24: 377-83.
3. Kim WR, Poterucha JJ, Wiesner RH, LaRusso NF, Lindor KD, Petz J, et al., The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology. 1999; 29: 1643-8.
4. Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al., A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000; 75: 688-94.
5. Solano E, Khakhar A, Bloch M, Quan D, McAlister V, Ghent C, et al., Liver transplantation for primary sclerosing cholangitis. Transpl Proc. 2003; 35: 2431-4.
6. Lindor KD,. Ursodiol for primary sclerosing cholangitis. N Engl J Med. 1997; 336: 691-5.
7. Olsson R, Boberg KM, Schaffalitsky de Muckadell O, Lindgren S, Hultcrantz R, Folvik G, et al., High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005; 129: 1464-72.
8. Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VAC, Edwyn Harrison M, et al., High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011; 34: 1185-92.
9. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al., High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009; 50: 808-14.
10. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VAC, et al., High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011; 106: 1638-45.
11. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW,. Improvement of serum alkaline phosphatase to < 1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2013; 58: 329-34.
12. Takikawa H, Takamori Y, Tanaka A, Kurihara H, Nakanuma Y,. Analysis of 388 cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res. 2004; 29: 153-9.
13. Hirano K, Tada M, Isayama H, Yashima Y, Yagioka H, Sasaki T, et al., Clinical features of primary sclerosing cholangitis with onset age above 50 years. Gastroenterology. 2008; 43: 729-33.
14. Lindor KD, LaRusso NF,. Primary sclerosing cholangitis. In:, Schiff ER, Sorrell MD, Maddrey WC, editors. Schiff's Diseases of the Liver, 9th edn. Philadelphia: Lippincott Williams and Wilkins; 2003. p. 673-84.
15. Stanich PP, Björnsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD,. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis. 2011; 43: 309-13.
16. Beuers U, Spengler U, Kruis W, Aydemir ü, Wiebecke B, Heldwein W, et al., Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology. 1992; 16: 707-14
17. Chazouillères O, Poupon R, Capron J-P, Metman E-H, Dhumeaux D, Amouretti M, et al., Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol. 1990; 11: 120-3.
18. Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD,. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 2001; 96: 1558-62.
19. O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G,. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology. 1991; 14: 838-47.
20. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW,. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol. 2008; 48: 792-800.
21. Othman MO, Dunkelberg J, Roy PK,. Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review. Arab J Gastroenterol. 2012; 13: 103-10.
22. Shi J, Li Z, Zeng X, Lin Y, Xie WF,. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res. 2009; 39: 865-73.